<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05100836</url>
  </required_header>
  <id_info>
    <org_study_id>Surpass</org_study_id>
    <nct_id>NCT05100836</nct_id>
  </id_info>
  <brief_title>SURPASS Impella 5.5 Study</brief_title>
  <official_title>SURPASS Study - The Surgical Unloading Renal Protection And Sustainable Support Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abiomed Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abiomed Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, prospective &amp; retrospective, observational single-arm study of the clinical&#xD;
      outcomes up to one year collected from electronic health records of patients which have&#xD;
      undergone standard of care implantation of Impella 5.5, regardless of clinical situation or&#xD;
      indication. All patients will be enrolled via an IRB-approved Waiver of Informed Consent and&#xD;
      HIPAA Authorization.&#xD;
&#xD;
      All patients who were supported retrospectively (prior to site IRB approval) with Impella 5.5&#xD;
      at the investigative site will be entered into the SURPASS registry and specified as the&#xD;
      retrospective cohort.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Anticipated">November 21, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 21, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival Outcome</measure>
    <time_frame>One year</time_frame>
    <description>The rate of patients who survived at Impella 5.5 explant, hospital discharge and follow-up up to 1 year</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Cardiogenic Shock</condition>
  <condition>Acute Decompensated Heart Failure</condition>
  <arm_group>
    <arm_group_label>Single arm all comers supported with Impella 5.5</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Impella 5.5</intervention_name>
    <description>Impella 5.5 mechanical circulatory support</description>
    <arm_group_label>Single arm all comers supported with Impella 5.5</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 18 years old and older who previously received an Impella 5.5 implant at the study&#xD;
        site&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Subject has previously undergone an Impella 5.5 implant at a study site&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not receiving Impella 5.5&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masahiro Ono, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist San Antonio Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Anderson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hackensack Meridian Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Danny Ramzy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David D'Alessandro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MGH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gundars Katlaps, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampa General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony Lemaire, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert Wood Johnson University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Soltesz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amin Medjamia, MD</last_name>
    <phone>978-646-1740</phone>
    <email>amedjamia@abiomed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oksana Bradley, MD</last_name>
    <phone>978-317-7982</phone>
    <email>obradley@abiomed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <email>carmelita.runyan@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Danny Ramzy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <email>alensisic@usf.edu</email>
    </contact>
    <investigator>
      <last_name>Gundars Katlaps, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MGH</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <email>kdrezek@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>David D'Alessandro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <email>&lt;stephanie.lynes@hmhn.org&gt;</email>
    </contact>
    <investigator>
      <last_name>Mark Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coordinator</last_name>
      <email>dl945@rwjms.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony Lemaire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coordinator</last_name>
      <email>LICINAC@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Edward Soltesz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist San Antonio Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <email>Sally.Mathews@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Masahiro Ono, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Impella</keyword>
  <keyword>Impella 5.5</keyword>
  <keyword>Bridge to next therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

